{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:15Z","timestamp":1785269895143,"version":"3.55.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jneuroim.2021.577702","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T22:42:23Z","timestamp":1629931343000},"page":"577702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"360","author":[{"given":"Negar","family":"Molazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki G.","family":"Filippatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni S.","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias S.","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577702_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/ICU.0b013e32835f8bf8","article-title":"Optical coherence tomography--current and future applications","volume":"24","author":"Adhi","year":"2013","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2017.10.001","article-title":"Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica","volume":"313","author":"Akaishi","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0015","doi-asserted-by":"crossref","first-page":"577467","DOI":"10.1016\/j.jneuroim.2020.577467","article-title":"Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders","volume":"351","author":"Akaishi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167473","article-title":"Retinal morphology and sensitivity are primarily impaired in eyes with neuromyelitis optica spectrum disorder (NMOSD)","volume":"11","author":"Akiba","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/WNO.0b013e3182893dd1","article-title":"Subclinical optic neuritis in neuromyelitis optica","volume":"33","author":"Aksoy","year":"2013","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0030","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.msard.2019.01.053","article-title":"MOG antibody disease manifesting as progressive cognitive deterioration and behavioral changes with primary central nervous system vasculitis","volume":"30","author":"Baba","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0045","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0050","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00415-017-8615-8","article-title":"Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France","volume":"264","author":"Biotti","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/NRL.0b013e31820a9d35","article-title":"A review of cases of neuromyelitis optica","volume":"17","author":"Bomprezzi","year":"2011","journal-title":"Neurologist."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.preteyeres.2006.05.003","article-title":"Muller cells in the healthy and diseased retina","volume":"25","author":"Bringmann","year":"2006","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0070","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fneur.2019.01157","article-title":"Brain atrophy in relapsing optic neuritis is associated with crion phenotype","volume":"10","author":"Canto","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0075","doi-asserted-by":"crossref","first-page":"102475","DOI":"10.1016\/j.msard.2020.102475","article-title":"Brain MRI characteristics in neuromyelitis optica spectrum disorders: a large multi-center retrospective study in China","volume":"46","author":"Cao","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0080","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol. (R) Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0085","doi-asserted-by":"crossref","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum Neurofilament light and GFAP are associated with disease severity in inflammatory disorders with Aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fneur.2020.00035","article-title":"The detection of retina microvascular density in subclinical Aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11940-018-0496-3","article-title":"Disease-modifying treatment in progressive multiple sclerosis","volume":"20","author":"Ciotti","year":"2018","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0110","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0115","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0120","doi-asserted-by":"crossref","first-page":"P02.149","DOI":"10.1212\/WNL.80.7_supplement.P02.149","article-title":"Incidence and clinical characteristics of secondary progressive neuromyelitis optica (P02.149)","volume":"80","author":"Cortez","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0125","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000313","article-title":"Finding NMO","volume":"4","author":"Daneman","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0135","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0140","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.neurad.2019.06.001","article-title":"MRI features of demyelinating disease associated with anti-MOG antibodies in adults","volume":"46","author":"Den\u00e8ve","year":"2019","journal-title":"J. Neuroradiol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0145","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3389\/fimmu.2018.02753","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disorders: toward a new spectrum of inflammatory demyelinating CNS disorders?","volume":"9","author":"Di Pauli","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0150","doi-asserted-by":"crossref","first-page":"102342","DOI":"10.1016\/j.msard.2020.102342","article-title":"Atypical MOG antibody disease presenting with typical multiple sclerosis lesions","volume":"44","author":"Dolbec","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0155","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/dmcn.13757","article-title":"Retinal nerve fibre layer thinning is associated with worse visual outcome after optic neuritis in children with a relapsing demyelinating syndrome","volume":"60","author":"Eyre","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12974-016-0746-9","article-title":"Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G","volume":"13","author":"Felix","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ophtha.2012.07.066","article-title":"Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography","volume":"120","author":"Fernandes","year":"2013","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0170","doi-asserted-by":"crossref","first-page":"540156","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0175","article-title":"Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD","author":"Filippatou","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0180","article-title":"Optic neuritis-independent retinal atrophy in neuromyelitis optica spectrum disorder","author":"Filippatou","year":"2021","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0185","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1212\/WNL.53.8.1705","article-title":"MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic\u2019s neuromyelitis optica","volume":"53","author":"Filippi","year":"1999","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0190","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000229","article-title":"Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD","volume":"3","author":"Finke","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"S3","key":"10.1016\/j.jneuroim.2021.577702_bb0195","first-page":"230","article-title":"Quiescent MRI activity in neuromyelitis optica spectrum disorder: results from the N-MOmentum randomized placebo-controlled trial. MSVirtual 2020 \u2013 8th joint ACTRIMS-ECTRIMS meeting","volume":"26","author":"Friedemann Paul","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0200","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000038","article-title":"Secondary progression and innate immunity in NMO: a possible link to alemtuzumab therapy?","volume":"1","author":"Fujihara","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0205","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0210","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fneur.2018.00340","article-title":"Progressive demyelination in the presence of serum myelin oligodendrocyte glycoprotein-IgG: a case report","volume":"9","author":"Gil-Perotin","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0215","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/jnnp.2008.166207","article-title":"Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis","volume":"80","author":"Green","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0220","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0230","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0235","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0240","first-page":"189624","article-title":"Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis","volume":"2013","author":"Healy","year":"2013","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0245","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420945135","article-title":"Recent developments in MOG-IgG associated neurological disorders","volume":"13","author":"Hegen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0250","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0037-1604404","article-title":"MOG Spectrum disorders and role of MOG-antibodies in clinical practice","volume":"49","author":"Hennes","year":"2018","journal-title":"Neuropediatrics."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0260","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0265","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ana.24608","article-title":"Clinicopathological features in anterior visual pathway in neuromyelitis optica","volume":"79","author":"Hokari","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0270","first-page":"89","article-title":"Retinal ganglion cell-inner plexiform and nerve fiber layers in neuromyelitis optica","volume":"11","author":"Hu","year":"2018","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0275","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/bjophthalmol-2018-312231","article-title":"Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders","volume":"103","author":"Huang","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0280","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0285","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000965","article-title":"Investigating the presence of Interattack astrocyte damage in neuromyelitis optica spectrum disorder: longitudinal analysis of serum glial fibrillary acidic protein","volume":"8","author":"Hyun","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0040-1701371","article-title":"Clinical course, imaging characteristics, and therapeutic response in myelin oligodendrocyte glycoprotein antibody disease: a case series","volume":"11","author":"James","year":"2020","journal-title":"J. Neurosci. Rural Pract."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0295","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0300","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0305","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0310","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0320","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0325","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","article-title":"MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0330","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0335","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0340","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00415-016-8138-8","article-title":"Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder","volume":"263","author":"Jeong","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0345","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/ene.13266","article-title":"Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder","volume":"24","author":"Jeong","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0350","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0355","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations","volume":"19","author":"Jury\u0144czyk","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0360","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0365","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0370","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/archneur.57.3.355","article-title":"Progressive necrotic myelopathy: clinical course in 9 patients","volume":"57","author":"Katz","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0375","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1177\/1352458514521517","article-title":"Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis","volume":"20","author":"Katz Sand","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0380","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0385","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/1352458510377907","article-title":"A case of chronic progressive myelopathy","volume":"16","author":"Kim","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0390","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0395","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/ene.13321","article-title":"Diffusion tensor imaging of normal-appearing white matter in patients with neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"24","author":"Kim","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0400","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3988\/jcn.2018.14.2.200","article-title":"Optical coherence tomography versus visual evoked potentials for detecting visual pathway abnormalities in patients with neuromyelitis optica spectrum disorder","volume":"14","author":"Kim","year":"2018","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0405","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0410","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0415","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/jnnp.2010.208173","article-title":"The natural history of secondary progressive multiple sclerosis","volume":"81","author":"Koch","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0420","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/WNL.0000000000010403","article-title":"Progressive brain atrophy and white matter changes in MOG encephalomyelitis","volume":"95","author":"Kwon","year":"2020","journal-title":"Neurology."},{"issue":"16","key":"10.1016\/j.jneuroim.2021.577702_bb0425","doi-asserted-by":"crossref","first-page":"e2058","DOI":"10.1212\/WNL.0000000000011788","article-title":"Association of spectral-domain OCT with long-term disability worsening in multiple sclerosis","volume":"96","author":"Lambe","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0430","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1177\/1352458517729463","article-title":"Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis","volume":"24","author":"Lanzillo","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0435","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","article-title":"Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease","volume":"87","author":"Lechner","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0440","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010847","article-title":"Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder","volume":"95","author":"Lee","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0445","first-page":"573","article-title":"Mildly abnormal retinal function in transgenic mice without M\u00fcller cell aquaporin-4 water channels","volume":"43","author":"Li","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0450","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00330-017-4921-x","article-title":"Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS","volume":"28","author":"Liu","year":"2018","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0455","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/1352458517721053","article-title":"Multimodal characterization of gray matter alterations in neuromyelitis optica","volume":"24","author":"Liu","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0460","first-page":"1","article-title":"Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study","author":"Liu","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0465","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0470","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0475","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/WNO.0000000000000404","article-title":"Longitudinal study of retinal nerve fiber layer thickness and macular volume in patients with neuromyelitis optica spectrum disorder","volume":"36","author":"Manogaran","year":"2016","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0480","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.nicl.2016.05.014","article-title":"Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica","volume":"11","author":"Manogaran","year":"2016","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0485","doi-asserted-by":"crossref","first-page":"102964","DOI":"10.1016\/j.msard.2021.102964","article-title":"Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: a new mimicker of progressive multiple sclerosis?","volume":"52","author":"Marcucci","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0490","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1167\/iovs.08-1815","article-title":"Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica","volume":"49","author":"Merle","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0495","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0140-6736(18)30426-4","article-title":"Effective treatment of progressive MS remains elusive","volume":"391","author":"Metz","year":"2018","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577702_bb0500","first-page":"1","article-title":"Progressive myelopathy in a patient with pediatric onset neuromyelitis optica spectrum disorder: a case report and a mini review","volume":"29","author":"Moghadasi","year":"2020","journal-title":"Acta Neurol. Taiwanica"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0505","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0510","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1167\/iovs.11-9324","article-title":"Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography","volume":"53","author":"Monteiro","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0515","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000805","article-title":"Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"7","author":"Motamedi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0520","doi-asserted-by":"crossref","first-page":"618879","DOI":"10.3389\/fneur.2020.618879","article-title":"Optical coherence tomography and optical coherence tomography angiography findings after optic neuritis in multiple sclerosis","volume":"11","author":"Murphy","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0525","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/1352458519845116","article-title":"Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures","volume":"26","author":"Murphy","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0530","doi-asserted-by":"crossref","first-page":"476960","DOI":"10.1016\/j.jneuroim.2019.05.001","article-title":"MOG antibody seropositive aseptic meningitis: a new clinical phenotype","volume":"333","author":"Nagabushana","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0535","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/01.wnl.0000345042.53843.d5","article-title":"Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis","volume":"72","author":"Naismith","year":"2009","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0540","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/pgmj.2009.091389","article-title":"Neuromyelitis optica: an overview","volume":"86","author":"Nandhagopal","year":"2010","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0545","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0550","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000334","article-title":"Microstructural visual system changes in AQP4-antibody\u2013seropositive NMOSD","volume":"4","author":"Oertel","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflammation."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0555","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/jnnp-2018-318382","article-title":"Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study","volume":"89","author":"Oertel","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0560","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12974-019-1521-5","article-title":"Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study","volume":"16","author":"Oertel","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0565","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0570","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1179\/016164106X98279","article-title":"Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica?","volume":"28","author":"Okai","year":"2006","journal-title":"Neurol. Res."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0575","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/tjo.tjo_22_20","article-title":"Evaluation of retinal nerve fiber layer thickness and optic nerve functions in fellow eye of neuromyelitis optica with unilateral optic neuritis","volume":"10","author":"Ong Chin Feng","year":"2020","journal-title":"Taiwan J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0580","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1177\/1352458515578888","article-title":"A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"21","author":"Outteryck","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0585","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s00330-016-4282-x","article-title":"Brain parenchymal damage in neuromyelitis optica spectrum disorder - a multimodal MRI study","volume":"26","author":"Pache","year":"2016","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0590","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0595","article-title":"MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response","volume":"4","author":"Pandit","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0600","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/jnr.22437","article-title":"Deletion of aquaporin-4 renders retinal glial cells more susceptible to osmotic stress","volume":"88","author":"Pannicke","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0605","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2018-320249","article-title":"Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders","volume":"90","author":"Papadopoulou","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0610","doi-asserted-by":"crossref","first-page":"102608","DOI":"10.1016\/j.nicl.2021.102608","article-title":"Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: a longitudinal study","volume":"30","author":"Papadopoulou","year":"2021","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0615","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-019-09586-5","article-title":"MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity","volume":"267","author":"Papathanasiou","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0620","doi-asserted-by":"crossref","first-page":"102074","DOI":"10.1016\/j.msard.2020.102074","article-title":"MOG-antibody-associated hypertrophic pachymeningitis","volume":"42","author":"Papathanasiou","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0625","doi-asserted-by":"crossref","first-page":"102712","DOI":"10.1016\/j.msard.2020.102712","article-title":"Primary progression in NMOSD. Does it really exist?","volume":"48","author":"Parissis","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0630","doi-asserted-by":"crossref","first-page":"577143","DOI":"10.1016\/j.jneuroim.2019.577143","article-title":"Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum - a north Indian tertiary care Centre experience and review of literature","volume":"340","author":"Pedapati","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0635","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jns.2017.10.028","article-title":"Evaluation of the retinal nerve fiber layer in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"383","author":"Peng","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0640","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0645","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1177\/1352458519861603","article-title":"Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography","volume":"26","author":"Pisa","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0650","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1212\/WNL.0b013e318200d80c","article-title":"Absence of cortical demyelination in neuromyelitis optica","volume":"75","author":"Popescu","year":"2010","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0655","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Probstel","year":"2015","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0660","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflammation."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0665","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0670","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0675","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.0b013e3181af78b8","article-title":"Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies","volume":"73","author":"Ratchford","year":"2009","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0680","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they?","volume":"30","author":"Reindl","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0685","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000924","article-title":"Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders","volume":"8","author":"Rinaldi","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0690","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/1352458513503053","article-title":"Visual evoked potentials in neuromyelitis optica and its spectrum disorders","volume":"20","author":"Ringelstein","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0695","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008684","article-title":"Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders","volume":"94","author":"Ringelstein","year":"2020","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.jneuroim.2021.577702_bb0700","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/ene.14766","article-title":"Foveal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive","volume":"28","author":"Roca-Fernandez","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0705","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1212\/01.WNL.0000106946.08741.41","article-title":"Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica","volume":"62","author":"Rocca","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0710","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040609","article-title":"Optical coherence tomography angiography of peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder: a comparative study","volume":"10","author":"Rogaczewska","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0715","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jim-2019-001126","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0720","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/acn3.674","article-title":"Retinal measurements predict 10-year disability in multiple sclerosis","volume":"6","author":"Rothman","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0725","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ana.24487","article-title":"Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four-year study","volume":"78","author":"Saidha","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0730","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.23721","article-title":"Cognitive impairment and cortical degeneration in neuromyelitis optica","volume":"73","author":"Saji","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0735","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1177\/1352458519837705","article-title":"MOG antibody-associated encephalomyelitis\/encephalitis","volume":"25","author":"Salama","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0740","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","volume":"26","author":"Salama","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0745","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0750","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066151","article-title":"Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis","volume":"8","author":"Schneider","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jneuroim.2021.577702_bb0760","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0765","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sep\u00falveda","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0770","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0775","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ophtha.2018.06.022","article-title":"Differing structural and functional patterns of optic nerve damage in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"126","author":"Shen","year":"2019","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0780","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1212\/WNL.0b013e31828c2f7a","article-title":"In vivo identification of morphologic retinal abnormalities in neuromyelitis optica","volume":"80","author":"Sotirchos","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0785","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ana.25738","article-title":"Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy","volume":"87","author":"Sotirchos","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0790","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejrad.2017.07.002","article-title":"Analysis of brain and spinal cord lesions to occult brain damage in seropositive and seronegative neuromyelitis optica","volume":"94","author":"Sun","year":"2017","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0795","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0800","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0805","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00415-015-7674-y","article-title":"The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset","volume":"262","author":"Tedeholm","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0810","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/1352458517727604","article-title":"Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD)","volume":"24","author":"Tian","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0815","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/147323001204000427","article-title":"Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability","volume":"40","author":"Tomizawa","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0820","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1352458507084264","article-title":"Natural history of secondary-progressive multiple sclerosis","volume":"14","author":"Tremlett","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0825","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era","volume":"80","author":"University of California SFMSET","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0830","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000224","article-title":"Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions","volume":"3","author":"Ventura","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0835","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/1352458513519838","article-title":"Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders","volume":"20","author":"von Glehn","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0840","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjophthalmol-2013-304547","article-title":"Optical coherence tomography angiography of optic nerve head and parafovea in multiple sclerosis","volume":"98","author":"Wang","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0845","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12883-014-0246-4","article-title":"Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0850","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0855","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1177\/1352458515600246","article-title":"Progressive cerebral atrophy in neuromyelitis optica","volume":"21","author":"Warabi","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0860","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0865","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577702_bb0870","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0875","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"issue":"Suppl","key":"10.1016\/j.jneuroim.2021.577702_bb0880","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1002\/ana.410360704","article-title":"Natural history of multiple sclerosis","volume":"36","author":"Weinshenker","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0885","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0890","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0895","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of Eculizumab in Aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0900","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102166","article-title":"Efficacy and safety of monoclonal antibody therapy in Neuromyelitis Optica Spectrum disorders: evidence from randomized controlled trials","volume":"43","author":"Xue","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0910","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0915","doi-asserted-by":"crossref","first-page":"101394","DOI":"10.1016\/j.msard.2019.101394","article-title":"Atypical presentation of MOG-related disease: slowly progressive behavioral and personality changes following a seizure","volume":"36","author":"Yilmaz","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0920","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ophtha.2019.01.016","article-title":"Evidence of muller glial dysfunction in patients with Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder","volume":"126","author":"You","year":"2019","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0925","first-page":"1009","article-title":"Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica","volume":"27","author":"Yu","year":"2006","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0930","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1148\/radiol.2461062075","article-title":"Pathogenesis of normal-appearing white matter damage in neuromyelitis optica: diffusion-tensor MR imaging","volume":"246","author":"Yu","year":"2008","journal-title":"Radiology."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0935","article-title":"Alterations in the retinal vascular network and structure in MOG antibody-associated disease: an optical coherence tomography angiography study","author":"Yu","year":"2020","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0940","first-page":"1","article-title":"Alterations in the retinal vascular network and structure in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a longitudinal OCTA study","author":"Yu","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0945","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-016-0355-y","article-title":"Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO\/SD","volume":"4","author":"Zeka","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0950","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jocn.2018.06.052","article-title":"The application of RNFL thickness detection in early differential diagnosis among various types of idiopathic optic neuritis","volume":"55","author":"Zhang","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0955","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-019-09685-3","article-title":"Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population","volume":"267","author":"Zhang","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0960","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/bjophthalmol-2020-315842","article-title":"Comparison of macular structural and vascular changes in neuromyelitis optica spectrum disorder and primary open angle glaucoma: a cross-sectional study","volume":"105","author":"Zhang","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577702_bb0965","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821002290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821002290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:40:04Z","timestamp":1759048804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821002290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":193,"alternative-id":["S0165572821002290"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577702","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577702"}}